

Cancer treatment—immunotherapy agent name, systemic therapy agent or protocol name, text X[X(149)]

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Cancer treatment—immunotherapy agent name, systemic therapy agent or protocol name, text X[X(149)]

Identifying and definitional attributes

Metadata item type:	Data Element
Short name:	Immunotherapy agent name
Synonymous names:	Biological response modifier therapy, biological therapy, biotherapy
METEOR identifier:	393804
Registration status:	Health , Recorded 17/05/2011
Definition:	The name of the immunotherapy agent or protocol administered during the initial course of treatment for cancer, as represented by text.
Data Element Concept:	Cancer treatment—immunotherapy agent name
Value Domain:	Text X[X(149)]

Value domain attributes

Representational attributes

Representation class:	Text
Data type:	String
Format:	X[X(149)]
Maximum character length:	150

Data element attributes

Collection and usage attributes

Guide for use:	<p>Immunotherapy is cancer therapy that achieves its antitumor effect by altering the immune system or changing the host's response to the tumor cells.</p> <p>Each immunotherapy agent used during the initial treatment of the cancer should be recorded. The initial course of treatment includes all treatments administered to the patient from diagnosis and before disease progression or recurrence.</p> <p>Systemic therapy often involves treatment with a combination of agents. These may be known by acronyms but since details of drugs and acronyms may vary it is recommended that each agent be recorded.</p> <p>The name of each immunotherapy agent or protocol given as initial treatment is recorded regardless of whether the course of treatment is completed as intended, and regardless of the intent or timing of the immunotherapy.</p> <p>When recording immunotherapy/systemic therapy protocols, eviQ should be used wherever possible. If a single agent is being used or a protocol is not included in eviQ, then the full, generic name of any agent should be recorded preferably using the Australian Medicines Terminology (AMT), or if necessary, the Australian Medicines Handbook (AMH) or MIMS. If a generic name is not available because the drug is experimental or under patent protection, record the brand name.</p> <p>The eviQ protocol identifier number, where available, is recorded separately in the data element "Cancer treatment—systemic therapy agent protocol, eviQ protocol identifier, NNNNNN".</p> <p>Oral immunotherapy normally given on an outpatient basis should also be included.</p> <p>The name(s) of other systemic treatment agents such as chemotherapy are collected as separate data items. However, if a patient receives treatment with a protocol that includes different types of systemic therapy agents, for example, a chemotherapy agent and an immunotherapy agent, record the protocol or agent names in both relevant data items.</p>
-----------------------	---

Collection methods:	This information should be collected from the patient's medical record.
Comments:	The collection of specific treatment information is useful to evaluate patterns of care, the effectiveness of different treatment modalities, and treatment by patient outcome.

Source and reference attributes

Submitting organisation:	Cancer Australia.
Origin:	National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program.
Reference documents:	<p>Standard Cancer Treatment and Management Pathways Program, Cancer Services and Education Division. eviQ Cancer Treatments Online. Cancer Institute NSW.</p> <p>The National Clinical Terminology and Information Service (NCTIS) 2011. Australian Medicines Terminology (AMT). Sydney: National E-Health Transition Authority (NEHTA). AMT releases are provided every month and are available from the NCTIS Secure Website.</p> <p>Australian Medicines Handbook (AMH). Australian Medicines Handbook Pty Ltd.</p> <p>MIMS Medicines Information. St Leonards, New South Wales: UBM Medica Pty Ltd.</p> <p>American College of Surgeons 2002. Facility Oncology Registry Data Standards (FORDS), 2009 revision, Commission on Cancer.</p>

Relational attributes

**Related metadata
references:**

See also [Cancer treatment—immunotherapy completion date, DDMMYYYY
Health](#), Superseded 08/05/2014

See also [Cancer treatment—immunotherapy start date, DDMMYYYY
Health](#), Superseded 08/05/2014